Feline Hypereosinophilic Syndrome

Feline Hypereosinophilic Syndrome (HES) is an uncommon but serious disorder in cats characterized by persistent, marked elevation of circulating eosinophils (hypereosinophilia) accompanied by direct eosinophil-mediated organ damage [1]. It represents a heterogeneous group of conditions in which eosinophilic infiltration of multiple tissues leads to progressive organ dysfunction [1][5]. The syndrome must be distinguished from reactive eosinophilia caused by parasitism, allergy, or other identifiable underlying diseases, and from paraneoplastic eosinophilia secondary to neoplasms such as intestinal T-cell lymphoma [3][4]. Without treatment, the progressive tissue destruction caused by eosinophilic infiltration renders HES a life-threatening condition [1][2].

The precise etiology of primary (idiopathic) feline HES remains incompletely understood; however, the underlying mechanism centers on dysregulated eosinophil production, mobilization, and tissue infiltration [5].

Pathological Mechanism: Eosinophils are granulocytes whose production in the bone marrow is regulated primarily by interleukin-5 (IL-5), along with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF). In HES, overproduction or abnormal stimulation leads to persistent peripheral blood eosinophil counts exceeding 5 × 10⁹/L (>5,000/µL), the threshold used to define hypereosinophilia in cats [5]. Activated eosinophils release cytotoxic granule proteins — including major basic protein (MBP), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin — that directly damage parenchymal cells of any infiltrated organ, including the myocardium, gastrointestinal mucosa, liver, spleen, skin, and bone marrow [1][2][5].

Primary vs. Secondary HES:

• ·Primary (idiopathic) HES: No underlying cause is identified. Eosinophilic expansion is thought to arise from intrinsic myeloproliferative dysregulation [5].
• ·Secondary (paraneoplastic) HES: Neoplastic cells, particularly intestinal T-cell lymphoma, can elaborate cytokines (notably IL-5) that drive reactive eosinophilia indistinguishable from primary HES on peripheral blood evaluation alone [3][4]. In one reported case, histopathological examination at necropsy confirmed intestinal T-cell lymphosarcoma as the underlying cause of severe hypereosinophilia [3]; another case documented epitheliotropic T-lymphocytic intestinal infiltration alongside bone marrow eosinophilic hyperplasia [4].
• ·Reactive eosinophilia (parasitic, allergic, or other causes) must be excluded before a diagnosis of primary HES is made [5].

Cardiac Pathophysiology: Eosinophilic infiltration of the myocardium causes direct cardiomyocyte injury and may progress to endomyocardial fibrosis, myocardial dysfunction, congestive heart failure, and pleural effusion — a well-documented pathway in affected cats [1].

Diagnosis of feline HES is one of exclusion and requires demonstration of persistent hypereosinophilia with organ damage after ruling out all secondary causes [1][5].

Hematology and Peripheral Blood:

• ·Complete blood count (CBC) typically reveals a markedly elevated eosinophil count exceeding 5 × 10⁹/L (>5,000/µL) [5]; counts may be dramatically higher in severe cases [4]
• ·Concurrent anemia (reduced HCT) may be present due to gastrointestinal blood loss (hematochezia, hematemesis) or bone marrow infiltration [4]
• ·Leukocytosis with eosinophilia as the predominant finding; WBC differential is essential to quantify the eosinophil fraction [3][5]
• ·Thrombocytopenia (reduced PLT) is possible in advanced myeloproliferative disease [5]

Serum Biochemistry:

• ·Elevated ALT and other hepatic enzymes if hepatic eosinophilic infiltration is present [5]
• ·Hypoalbuminemia (low ALB) may reflect protein-losing enteropathy in cases with significant gastrointestinal involvement [3]
• ·Elevated globulins (GLOB) may be noted in chronic inflammatory states
• ·BUN and CREA elevations indicate renal involvement or prerenal azotemia from poor perfusion in heart failure [1]

Cardiac Biomarkers:

• ·Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) supports myocardial stress; this biomarker was documented in a cat presenting with eosinophilic cardiac infiltration and congestive heart failure [1]

Bone Marrow Aspiration/Biopsy:

• ·Reveals moderate to marked eosinophilic hyperplasia with increased eosinophilic lineage precursors, confirming autonomous eosinophil overproduction [4][5]
• ·Essential to distinguish primary myeloproliferative HES from reactive eosinophilia

Cytology and Histopathology:

• ·Cytological examination of effusions (peritoneal, pleural) typically demonstrates eosinophilic exudate [3]
• ·Tissue biopsy of affected organs (intestine, lymph nodes, liver, myocardium) shows dense eosinophilic infiltration and, if applicable, underlying neoplasia [3][4]
• ·Immunohistochemistry for T-cell markers (e.g., CD3) is important to identify paraneoplastic T-cell lymphoma as the cause of secondary HES [3][4]

Diagnostic Imaging:

• ·Thoracic radiography and echocardiography are indicated in cats with dyspnea or murmur; echocardiography can reveal myocardial thickening, valvular abnormalities, pleural effusion, and reduced cardiac function [1]
• ·Abdominal ultrasonography may identify intestinal wall thickening, mesenteric lymphadenopathy, hepatosplenomegaly, and free peritoneal fluid [3]

Exclusion Criteria:

• ·Comprehensive parasite screening (fecal flotation, heartworm testing) to exclude parasitic eosinophilia [5]
• ·Allergy workup and dietary trials to rule out hypersensitivity-driven reactive eosinophilia [5]
• ·Thorough neoplasia screening (imaging, biopsy) to exclude paraneoplastic HES [3][4]

Treatment of feline HES is directed at suppressing eosinophil production and infiltration, managing organ-specific complications, and — in secondary HES — addressing the underlying disease.

Immunosuppressive / Anti-eosinophilic Therapy:

• ·Glucocorticoids (prednisolone) are the mainstay of treatment. Prednisolone inhibits eosinophil survival, migration, and cytokine production. In reported cases, prednisolone administration produced initial clinical improvement and temporary resolution or reduction of peripheral eosinophilia [3][4]. Doses typically employed are immunosuppressive (e.g., 2–4 mg/kg/day initially, tapered according to response).
• ·Hydroxyurea (hydroxycarbamide) has been used as a cytoreductive agent in cats with myeloproliferative HES refractory to glucocorticoids alone, targeting excessive eosinophil production in the bone marrow [5].
• ·Chlorambucil may be considered as an adjunct immunosuppressive agent, particularly in cases associated with lymphoproliferative disease [3][5].
• ·Vincristine and other cytotoxic protocols have been described in the management of cases with concurrent T-cell lymphoma [3][4].

Cardiac Management:

• ·Cats presenting with congestive heart failure secondary to eosinophilic myocardial infiltration require concurrent cardiac therapy [1].
• ·Furosemide (loop diuretic) is indicated for managing pleural or pulmonary edema.
• ·Antithrombotic therapy (e.g., clopidogrel or aspirin) may be warranted given the risk of thromboembolic disease associated with eosinophilic endocardial damage [1].
• ·Thoracocentesis for relief of large pleural effusions [1].

Supportive Care:

• ·Nutritional support, including assisted feeding, for cats with marked weight loss and anorexia [4]
• ·Intravenous fluid therapy to correct dehydration or hemodynamic compromise
• ·Antiparasitic treatment should be administered empirically if parasitism cannot be definitively excluded [5]
• ·Treatment of secondary HES must target the underlying condition (e.g., chemotherapy for intestinal T-cell lymphoma) [3][4]

The prognosis for feline HES is generally guarded to poor, particularly when cardiac involvement, bone marrow infiltration, or underlying neoplasia is identified [1][3][4].

Key Prognostic Findings from the Literature:

• ·In cases of paraneoplastic HES secondary to intestinal T-cell lymphoma, the disease course is typically progressive and fatal. In one reported case, the cat showed a temporary response to glucocorticoids but clinical signs progressed and the animal was euthanized [3]. A second case documented eventual fatal deterioration despite initial remission [4].
• ·Cardiac infiltration with eosinophilic HES carries an especially grave prognosis; eosinophilic myocardial damage, heart failure, and thromboembolic risk compound the systemic burden of disease [1].
• ·Primary idiopathic HES may respond more durably to glucocorticoid therapy than secondary forms, but long-term remission is difficult to achieve and relapse is common [5].

Important note: The currently available peer-reviewed literature on feline HES consists largely of individual case reports and small case series. No large-scale epidemiological study providing explicit overall survival statistics, median survival times, or population-level case-fatality rates for feline HES was identified among the references cited above. Based on the consistent pattern of fatal outcomes reported in published cases, especially those with cardiac or neoplastic involvement, the condition carries a high case-fatality rate in clinical practice. Owners should be counseled accordingly.

There are currently no established preventive strategies specific to feline Hypereosinophilic Syndrome, reflecting the poorly understood etiology of the primary idiopathic form and the paraneoplastic nature of secondary cases.

General Recommendations:

• ·Parasite control: Rigorous and regular broad-spectrum antiparasitic treatment (intestinal helminths, heartworm prevention in endemic areas) reduces the likelihood of reactive eosinophilia and may minimize the background eosinophilic burden [5].
• ·Allergy management: Identifying and managing underlying hypersensitivities (food, environmental) through appropriate dietary trials and allergen avoidance helps prevent chronic eosinophilic stimulation that could predispose to dysregulated responses [5][2].
• ·Routine health monitoring: Regular veterinary examinations including CBC in middle-aged to older cats can facilitate early detection of rising eosinophil counts before overt organ damage develops [1][3].
• ·Neoplasia surveillance: Given the documented association between intestinal T-cell lymphoma and paraneoplastic HES, early investigation of gastrointestinal signs (weight loss, vomiting, diarrhea) in older cats — with abdominal ultrasonography and biopsy when indicated — may lead to earlier diagnosis of the underlying neoplasm [3][4].
• ·No vaccine exists for HES, and no specific dietary supplement or management protocol has been demonstrated in controlled studies to prevent the condition.